Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurobiological Technologies and the Buck Institute for Age Research have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's disease.
Subscribe to our email newsletter
Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse the symptoms of Alzheimer’s disease. As part of this agreement, Neurobiological Technologies has agreed to fund a joint research collaboration with the Buck relating to the Alzheimer’s drug development for up to three years. Research funding for the initial year under the agreement will total $1.2 million.
In consideration for the license, Neurobiological Technologies will pay upfront license fees totaling $175,000 over a three-year period. This agreement is the second collaboration between Neurobiological Technologies and Buck focused on central nervous system conditions.
Paul Freiman, president and CEO of Neurobiological Technologies, said: “The partnership with the Buck Institute has the potential to expand our pipeline of product candidates in central nervous system disorders.”